Menu Search
Equities

Masimo Corp

MASI:NSQ

Masimo Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)171.64
  • Today's Change2.51 / 1.49%
  • Shares traded211.84k
  • 1 Year change+85.27%
  • Beta0.9939
Data delayed at least 15 minutes, as of Nov 22 2024 16:44 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy3
Outperform4
Hold3
Sell0
Strong Sell0

Share price forecast in USD

The 8 analysts offering 12 month price targets for Masimo Corp have a median target of 174.50, with a high estimate of 190.00 and a low estimate of 145.00. The median estimate represents a 3.18% increase from the last price of 169.12.
High12.3%190.00
Med3.2%174.50
Low-14.3%145.00

Earnings history & estimates in USD

On Nov 05, 2024, Masimo Corp reported 3rd quarter 2024 earnings of 0.98 per share. This result exceeded the 0.84 consensus of the 9 analysts covering the company and exceeded last year's 3rd quarter results by 55.56%.
The next earnings announcement is expected on Feb 24, 2025.
Average growth rate+16.63%
Masimo Corp reported annual 2023 earnings of 3.17 per share on Feb 27, 2024.
Average growth rate+1.68%
More ▼

Revenue history & estimates in USD

Masimo Corporation had 3rd quarter 2024 revenues of 504.60m. This bettered the 502.67m consensus of the 8 analysts covering the company. This was 10.69% below the prior year's 3rd quarter results.
Average growth rate+1.69%
Masimo Corporation had revenues for the full year 2023 of 2.05bn. This was 0.60% above the prior year's results.
Average growth rate+23.80%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.